FAM188B2 Inhibitors
FAM188B2 inhibitors encompass a range of chemical compounds that attenuate the functional activity of FAM188B2 by targeting various signaling pathways and cellular processes. Staurosporine, a broad-spectrum kinase inhibitor, can disrupt multiple signaling cascades, potentially leading to reduced phosphorylation and subsequent activity of FAM188B2, given kinase regulation is a part of its functional mechanism. Similarly, LY 294002 and Wortmannin, which are PI3K inhibitors, could reduce FAM188B2 activity by disrupting the PI3K/Akt signaling axis, a common modulator of cellular functions. Rapamycin's selective inhibition of mTOR could suppress FAM188B2 activity by interfering with the mTOR pathway, which is often associated with regulation of cell growth and proliferation. Furthermore, the specific MAPK pathway inhibitors PD 98059, SB 203580, and U0126 can impede signaling through ERK andp38 MAPK, which may indirectly lead to a decrease in FAM188B2 activity if it is modulated by these kinases. Compounds such as SP600125 and Gö 6983, which inhibit JNK and PKC respectively, could also result in diminished FAM188B2 activity if it is regulated by these pathways.
In addition to kinase inhibitors, other compounds that target distinct cellular processes can indirectly inhibit FAM188B2. For instance, NF449, by inhibiting the Gs-alpha subunit, could lower cAMP levels and thereby potentially decrease FAM188B2 activity if cAMP-dependent pathways regulate it. Calcium signaling modulator BAPTA/AM might limit FAM188B2 function by chelating intracellular calcium, which is crucial for various signaling pathways. Y-27632, a selective ROCK inhibitor, could downregulate FAM188B2 activity if Rho/ROCK signaling is involved in its regulation. Collectively, these chemical inhibitors operate through diverse mechanisms, but all converge on the common outcome of attenuating the functional activity of FAM188B2 by manipulating the signaling pathways and cellular processes that govern its role in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting a broad range of kinases, it can disrupt various signaling pathways, potentially leading to decreased phosphorylation and activity of FAM188B2 if the protein is regulated by kinase activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can lead to reduced activation of downstream targets such as Akt, which could indirectly diminish the function of FAM188B2 if it is part of the PI3K/Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR, a key regulator of cell growth and proliferation. If FAM188B2 function is linked to mTOR signaling, rapamycin could lead to reduced activity of FAM188B2 by inhibiting this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 could decrease the activity of ERK, which may indirectly affect FAM188B2 activity if FAM188B2 is regulated by the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. If FAM188B2 is involved in the p38 MAPK signaling pathway, inhibition by SB 203580 could lead to diminished activity of FAM188B2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. Inhibition of this pathway could indirectly lead to decreased activity of FAM188B2 if it is regulated through this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. By inhibiting PI3K, it could indirectly decrease FAM188B2 activity by disrupting the PI3K/Akt signaling pathway if FAM188B2 is a downstream effector. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If FAM188B2 activity is modulated through the JNK signaling pathway, inhibition by SP600125 could lead to a decrease in FAM188B2 functional activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha, the G protein subunit. By inhibiting Gs-alpha, NF449 could decrease cAMP levels, potentially affecting FAM188B2 activity if FAM188B2 is modulated by cAMP-dependent pathways. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA/AM is a selective, membrane-permeable calcium chelator. By chelating intracellular calcium, it may indirectly diminish FAM188B2 activity if FAM188B2 is regulated by calcium-dependent signaling pathways. | ||||||